Ezetimibe (Ezetrol®), which is used to treat hypercholesterolaemia in combination with a statin, has been granted a new indication by the Medicines and Healthcare products Regulatory Agency (MHRA). The drug is now also indicated to reduce the risk of cardiovascular events in patients with coronary heart disease and a history of acute coronary syndrome when added to ongoing statin therapy or started with a statin.
A major study funded by the National Institute for Health Research concludes that more frequent lipid monitoring strategies are cost-effective when compared with other longer interval strategies to guide treatment for prevention of cardiovascular disease.
Some fat is essential for maintaining good health, in order to provide essential fatty acids and the fat-soluble vitamins A, D, E and K. Essential fatty acids can only be derived from foods because they cannot be synthesised by the body. However, the hard truth is that essential fatty acids represent only a very small amount of total energy needs and most people still consume too much fat. How much fat should we be eating? What is the difference between different types of fats and what advice should we be giving patients about fats to reduce their risk of cardiovascular disease?
*The British Journal of Primary Care Nursing approached Merck Sharp & Dohme Limited to fund the production of this supplement following a meeting the company supported at the Primary Care Cardiovascular Society (PCCS) Conference 2009. The company was not involved in development, although it was asked to review the supplement for technical accuracy just prior to printing. Editorial control has remained with the British Journal of Primary Care Nursing at all times.
Detailed results from the FOURIER cardiovascular outcomes trial on evolocumab were presented at a late-breaking oral presentation at the American College of Cardiology meeting in Washington DC recently. This is the first major outcomes study to be published for a PCSK9 inhibitor – a new class of cholesterol-lowering medicines.
Adding evolocumab to optimised statin therapy results in statistically significant regression of atherosclerosis in patients with coronary artery disease, according to results from the GLAGOV phase 3 trial.